Compare

QuidelOrtho Corporation/$QDEL

1D1W1M3M6MYTD1Y5YMAX

About QuidelOrtho Corporation

QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.
Ticker
$QDEL
Sector
Health
Primary listing
NASDAQ
Employees
6,500

QDEL Metrics

BasicAdvanced
$737M
-
-$5.40
0.80
-

What the Analysts think about QDEL

Analyst ratings (Buy, Hold, Sell) for QuidelOrtho Corporation stock.
Analyst projections of the future price of QuidelOrtho Corporation stock.

Bulls say / Bears say

Core Labs and immunohematology are still growing outside China: in Q3, they rose 4% and 3% respectively in constant currency. Excluding China, respiratory and the donor-screening wind-down, total revenue grew 3%, pointing to resilience beneath the weak headline result. (QuidelOrtho, The Motley Fool)
The new restructuring programme is expected to deliver more than $80 million in annual savings in 2027. If achieved, that could strengthen margins and cash generation as the company manages current market pressures. (QuidelOrtho)
New products offer a possible growth engine: QuidelOrtho is expanding its VITROS 450 launch internationally and building placements for its NULEXA point-of-care molecular platform. Management says early customer engagement with NULEXA is encouraging and sees scope to expand its test menu. (The Motley Fool)
China is a sharp and persistent headwind: Q3 revenue fell 45% year on year as customers reduced orders amid pricing changes and destocking. Management expects more destocking through 2026 and further pricing pressure in 2027. (The Motley Fool)
Weak respiratory demand is dragging on Point of Care: revenue fell 27% in Q3, including a 39% drop in respiratory sales. The unpredictable season makes a near-term rebound uncertain. (QuidelOrtho, The Motley Fool)
High debt and weak cash conversion leave little room for setbacks: net debt was about $2.8 billion and leverage was 4.5 times adjusted EBITDA, while Q3 free cash flow was nearly flat. Lower earnings or delays in savings could make deleveraging harder. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.

QDEL Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

QDEL Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.